tirzepatide surmount-1 nejm 2022 weight loss percent 📊 Semaglutide 2.4mg: −13.7% (SURMOUNT-5 head-to-head), 📊 15mg: −20.2% weight loss (same trial, 2025), 📊 Retatrutide 12mg: −28.7% weight loss (TRIUMPH-4, Phase 3, Dec Choose Preference:No Additives MAP Cardiovascular disease continuum-GLP-1 action.

tirzepatide surmount-1 nejm 2022 weight loss percent 📊 Semaglutide 2.4mg: −13.7% (SURMOUNT-5 head-to-head), 📊 15mg: −20.2% weight loss (same trial, 2025), 📊 Retatrutide 12mg: −28.7% weight loss (TRIUMPH-4, Phase 3, Dec Choose Preference:No Additives MAP Cardiovascular disease continuum-GLP-1 action.

Cardiovascular disease continuum-GLP-1 action. Adapted from [46] | Download Scientific Diagram

[DOI] [PMC free article] [PubMed] [Google Scholar] 124.Kosiborod M.N., Esterline R., Furtado R.H.M., Oscarsson J., Gasparyan S.B., Koch G.G., Martinez F., Mukhtar O., Verma S., Chopra V., et al

MAP

Choose Preference:No Additives

Although this may sound appealing initially, regularly eating too little can make it difficult to meet your protein, vitamin and mineral requirements